Proactiveinvestors United Kingdom Companies https://www.biotech-capital.com Proactiveinvestors United Kingdom Companies RSS feed en Sun, 20 Oct 2019 00:29:20 +0100 http://blogs.law.harvard.edu/tech/rss Genera CMS action@proactiveinvestors.com (Proactiveinvestors) action@proactiveinvestors.com (Proactiveinvestors) https://www.biotech-capital.com/companies/news/905171/buds--duds-cannabis-stocks-quiet-into-the-weekend-after-milestone-week-in-marijuana-905171.html Buds & Duds: Cannabis stocks quiet into the weekend after milestone week in marijuana https://www.biotech-capital.com/companies/news/905171/buds--duds-cannabis-stocks-quiet-into-the-weekend-after-milestone-week-in-marijuana-905171.html Fri, 18 Oct 2019 16:26:00 +0100 https://www.biotech-capital.com/companies/news/905160/aequus-pharmaceuticals-highlights-new-research-showing-vistitan-s-effectiveness-at-treating-glaucoma-905160.html Aequus Pharmaceuticals highlights new research showing Vistitan's effectiveness at treating glaucoma https://www.biotech-capital.com/companies/news/905160/aequus-pharmaceuticals-highlights-new-research-showing-vistitan-s-effectiveness-at-treating-glaucoma-905160.html Fri, 18 Oct 2019 15:09:00 +0100 https://www.biotech-capital.com/companies/news/905158/volitionrx-s-nuq-platform-to-be-touted-at-major-veterinary-conference-in-houston-905158.html VolitionRX's Nu.Q platform to be touted at major veterinary conference in Houston https://www.biotech-capital.com/companies/news/905158/volitionrx-s-nuq-platform-to-be-touted-at-major-veterinary-conference-in-houston-905158.html Fri, 18 Oct 2019 14:46:00 +0100 https://www.biotech-capital.com/companies/news/905159/astrazeneca-likely-to-remain-in-favour-banks-update-on-ppi-905159.html AstraZeneca likely to remain in favour, banks update on PPI https://www.biotech-capital.com/companies/news/905159/astrazeneca-likely-to-remain-in-favour-banks-update-on-ppi-905159.html Fri, 18 Oct 2019 14:44:00 +0100 https://www.biotech-capital.com/companies/news/905153/avacta-raises-9mln-as-its-moves-towards-first-affimer-trial-905153.html Avacta raises £9mln as its moves towards first affimer trial https://www.biotech-capital.com/companies/news/905153/avacta-raises-9mln-as-its-moves-towards-first-affimer-trial-905153.html Fri, 18 Oct 2019 14:08:00 +0100 https://www.biotech-capital.com/companies/news/905118/dechra-pharma-still-working-to-fix-supply-problems-905118.html Dechra Pharma still working to fix supply problems https://www.biotech-capital.com/companies/news/905118/dechra-pharma-still-working-to-fix-supply-problems-905118.html Fri, 18 Oct 2019 07:38:00 +0100 https://www.biotech-capital.com/companies/news/905089/can-intercontinental-hotels-stop-more-investors-checking-out-905089.html Can InterContinental Hotels stop more investors checking out? https://www.biotech-capital.com/companies/news/905089/can-intercontinental-hotels-stop-more-investors-checking-out-905089.html Fri, 18 Oct 2019 06:00:00 +0100 https://www.biotech-capital.com/companies/news/905091/ipo-roundup-post-holdings--protein-spinoff-bellring-brands-lifts-its-way-to-480-million-ipo-905091.html IPO Roundup: Post Holdings' protein spinoff BellRing Brands lifts its way to $480 million IPO https://www.biotech-capital.com/companies/news/905091/ipo-roundup-post-holdings--protein-spinoff-bellring-brands-lifts-its-way-to-480-million-ipo-905091.html Thu, 17 Oct 2019 17:10:00 +0100 https://www.biotech-capital.com/companies/news/905090/buds--duds-pot-stocks-stay-quiet-a-year-following-cannabis-legalization-in-canada-905090.html Buds & Duds: Pot stocks stay quiet a year following cannabis legalization in Canada https://www.biotech-capital.com/companies/news/905090/buds--duds-pot-stocks-stay-quiet-a-year-following-cannabis-legalization-in-canada-905090.html Thu, 17 Oct 2019 17:00:00 +0100 https://www.biotech-capital.com/companies/news/905065/bioporto-submits-answers-to-fda-over-510k-application-for-ngal-test-905065.html BioPorto submits answers to FDA over 510(k) application for NGAL Test https://www.biotech-capital.com/companies/news/905065/bioporto-submits-answers-to-fda-over-510k-application-for-ngal-test-905065.html Thu, 17 Oct 2019 14:12:00 +0100 https://www.biotech-capital.com/companies/news/905020/oncimmune-welcomes-nhs-review-of-cancer-screening-programmes-905020.html Oncimmune welcomes NHS review of cancer screening programmes https://www.biotech-capital.com/companies/news/905020/oncimmune-welcomes-nhs-review-of-cancer-screening-programmes-905020.html Thu, 17 Oct 2019 10:09:00 +0100 https://www.biotech-capital.com/companies/news/221875/oncimmune-sees-more-successes-for-earlycdt-cancer-test-221875.html Oncimmune sees more successes for EarlyCDT cancer test https://www.biotech-capital.com/companies/news/221875/oncimmune-sees-more-successes-for-earlycdt-cancer-test-221875.html Thu, 17 Oct 2019 10:03:00 +0100 https://www.biotech-capital.com/companies/news/905040/fda-grants-priority-review-status-to-astrazenecas-breast-cancer-antibody-905040.html FDA grants “priority review” status to AstraZeneca’s breast cancer antibody https://www.biotech-capital.com/companies/news/905040/fda-grants-priority-review-status-to-astrazenecas-breast-cancer-antibody-905040.html Thu, 17 Oct 2019 09:22:00 +0100 https://www.biotech-capital.com/companies/news/905030/tissue-regenix-confirms-us300000-grant-for-san-antonio-facility-905030.html Tissue Regenix confirms US$300,000 grant for San Antonio facility https://www.biotech-capital.com/companies/news/905030/tissue-regenix-confirms-us300000-grant-for-san-antonio-facility-905030.html Thu, 17 Oct 2019 08:43:00 +0100 https://www.biotech-capital.com/companies/news/905022/sareum-holdings-poster-details-released-905022.html Sareum Holdings poster details released https://www.biotech-capital.com/companies/news/905022/sareum-holdings-poster-details-released-905022.html Thu, 17 Oct 2019 08:07:00 +0100 https://www.biotech-capital.com/companies/news/905016/verona-pharma-expects-data-from-clinical-trial-around-the-end-of-the-year-905016.html Verona Pharma expects data from clinical trial around the end of the year https://www.biotech-capital.com/companies/news/905016/verona-pharma-expects-data-from-clinical-trial-around-the-end-of-the-year-905016.html Thu, 17 Oct 2019 07:45:00 +0100 https://www.biotech-capital.com/companies/news/905007/imugene-appoints-world-renowned-cancer-researcher-physician-and-surgeon-to-head-up-ov-scientific-advisory-board-905007.html Imugene appoints world-renowned cancer researcher, physician and surgeon to head-up OV Scientific Advisory Board https://www.biotech-capital.com/companies/news/905007/imugene-appoints-world-renowned-cancer-researcher-physician-and-surgeon-to-head-up-ov-scientific-advisory-board-905007.html Thu, 17 Oct 2019 06:10:00 +0100 https://www.biotech-capital.com/companies/news/905003/thc-global-crosses-a-major-milestone-towards-producing-and-supplying-australian-medicinal-cannabis-905003.html THC Global crosses a major milestone towards producing and supplying Australian medicinal cannabis https://www.biotech-capital.com/companies/news/905003/thc-global-crosses-a-major-milestone-towards-producing-and-supplying-australian-medicinal-cannabis-905003.html Thu, 17 Oct 2019 03:39:00 +0100 https://www.biotech-capital.com/companies/news/904998/pharmaxis-cash-funds-for-development-of-new-drugs-boosted-by-62-million-rd-tax-incentive-904998.html Pharmaxis cash funds for development of new drugs boosted by $6.2 million R&D tax incentive https://www.biotech-capital.com/companies/news/904998/pharmaxis-cash-funds-for-development-of-new-drugs-boosted-by-62-million-rd-tax-incentive-904998.html Thu, 17 Oct 2019 02:24:00 +0100 https://www.biotech-capital.com/companies/news/904975/cosmos-holdings-hires-consultancy-exchange-listing-as-it-prepares-to-uplist-to-nasdaq-904975.html Cosmos Holdings hires consultancy Exchange Listing as it prepares to uplist to NASDAQ https://www.biotech-capital.com/companies/news/904975/cosmos-holdings-hires-consultancy-exchange-listing-as-it-prepares-to-uplist-to-nasdaq-904975.html Wed, 16 Oct 2019 19:10:00 +0100 https://www.biotech-capital.com/companies/news/904968/buds--duds-cannabis-stocks-reverse-nabis-holdings-jumps-after-securing-phoenix-dispensary-904968.html Buds & Duds: Cannabis stocks reverse; Nabis Holdings jumps after securing Phoenix dispensary https://www.biotech-capital.com/companies/news/904968/buds--duds-cannabis-stocks-reverse-nabis-holdings-jumps-after-securing-phoenix-dispensary-904968.html Wed, 16 Oct 2019 16:25:00 +0100 https://www.biotech-capital.com/companies/news/904452/faron-pharma-extremely-happy-with-progress-of-clevegen-trial-904452.html Faron Pharma “extremely happy” with progress of Clevegen trial https://www.biotech-capital.com/companies/news/904452/faron-pharma-extremely-happy-with-progress-of-clevegen-trial-904452.html Wed, 16 Oct 2019 16:07:00 +0100 https://www.biotech-capital.com/companies/news/904941/proactive-snapshot-instem-tekcapital-arkle-resources-904941.html Proactive snapshot: Instem, Tekcapital, Arkle Resources https://www.biotech-capital.com/companies/news/904941/proactive-snapshot-instem-tekcapital-arkle-resources-904941.html Wed, 16 Oct 2019 15:30:00 +0100 https://www.biotech-capital.com/companies/news/904952/orgenesis-inks-co-development-agreement-with-accellix-to-improve-quality-control-in-its-cellular-therapy-system-904952.html Orgenesis inks co-development agreement with Accellix to improve quality control in its cellular therapy system https://www.biotech-capital.com/companies/news/904952/orgenesis-inks-co-development-agreement-with-accellix-to-improve-quality-control-in-its-cellular-therapy-system-904952.html Wed, 16 Oct 2019 14:10:00 +0100 https://www.biotech-capital.com/companies/news/904938/futura-medical-to-share-data-at-us-sexual-medicine-conference-904938.html Futura Medical to share data at US sexual medicine conference https://www.biotech-capital.com/companies/news/904938/futura-medical-to-share-data-at-us-sexual-medicine-conference-904938.html Wed, 16 Oct 2019 10:13:00 +0100 https://www.biotech-capital.com/companies/news/904882/canaccord-initiates-coverage-of-medexus-pharmaceuticals-with-buy-rating-c650-price-target-904882.html Canaccord initiates coverage of Medexus Pharmaceuticals with Buy rating, C$6.50 price target https://www.biotech-capital.com/companies/news/904882/canaccord-initiates-coverage-of-medexus-pharmaceuticals-with-buy-rating-c650-price-target-904882.html Tue, 15 Oct 2019 17:50:00 +0100 https://www.biotech-capital.com/companies/news/904879/buds--duds-cannabis-stocks-get-back-to-growing-canntrust-begins-to-earn-back-investor-confidence-904879.html Buds & Duds: Cannabis stocks get back to growing; CannTrust begins to earn back investor confidence https://www.biotech-capital.com/companies/news/904879/buds--duds-cannabis-stocks-get-back-to-growing-canntrust-begins-to-earn-back-investor-confidence-904879.html Tue, 15 Oct 2019 16:39:00 +0100 https://www.biotech-capital.com/companies/news/904863/exactus-acquires-luxury-cannabinoid-infused-cosmetic-products-brand-levor-collection-904863.html Exactus acquires luxury cannabinoid-infused cosmetic products brand LeVor Collection https://www.biotech-capital.com/companies/news/904863/exactus-acquires-luxury-cannabinoid-infused-cosmetic-products-brand-levor-collection-904863.html Tue, 15 Oct 2019 14:30:00 +0100 https://www.biotech-capital.com/companies/news/904856/namaste-technologies-subsidiary-cannmart-approved-to-sell-cannabis-oil-concentrates-online-904856.html Namaste Technologies subsidiary CannMart approved to sell cannabis oil concentrates online https://www.biotech-capital.com/companies/news/904856/namaste-technologies-subsidiary-cannmart-approved-to-sell-cannabis-oil-concentrates-online-904856.html Tue, 15 Oct 2019 14:06:00 +0100 https://www.biotech-capital.com/companies/news/904765/seelos-therapeutics-names-industry-veteran-scott-applebaum-as-lead-strategic-regulatory-consultant-904765.html Seelos Therapeutics names industry veteran Scott Applebaum as lead strategic regulatory consultant https://www.biotech-capital.com/companies/news/904765/seelos-therapeutics-names-industry-veteran-scott-applebaum-as-lead-strategic-regulatory-consultant-904765.html Tue, 15 Oct 2019 14:05:00 +0100 https://www.biotech-capital.com/companies/news/904859/humanigen-contemplating-raising-funds-by-conducting-a-broadly-syndicated-rights-offering-904859.html Humanigen contemplating raising funds by conducting a broadly syndicated rights offering https://www.biotech-capital.com/companies/news/904859/humanigen-contemplating-raising-funds-by-conducting-a-broadly-syndicated-rights-offering-904859.html Tue, 15 Oct 2019 14:00:00 +0100 https://www.biotech-capital.com/companies/news/215154/sareum-holdings-primed-for-progress-215154.html Sareum Holdings primed for progress https://www.biotech-capital.com/companies/news/215154/sareum-holdings-primed-for-progress-215154.html Tue, 15 Oct 2019 09:18:00 +0100 https://www.biotech-capital.com/companies/news/214099/ixico-swings-into-profit-as-brain-data-analysis-sales-soar-214099.html IXICO swings into profit as brain data analysis sales soar https://www.biotech-capital.com/companies/news/214099/ixico-swings-into-profit-as-brain-data-analysis-sales-soar-214099.html Tue, 15 Oct 2019 09:15:00 +0100 https://www.biotech-capital.com/companies/news/904822/sareum-looks-towards-clinical-studies-for-novel-autoimmune-and-cancer-therapies-904822.html Sareum looks towards clinical studies for novel autoimmune and cancer therapies https://www.biotech-capital.com/companies/news/904822/sareum-looks-towards-clinical-studies-for-novel-autoimmune-and-cancer-therapies-904822.html Tue, 15 Oct 2019 08:58:00 +0100 https://www.biotech-capital.com/companies/news/904807/ixico-beats-forecasts-on-strong-demand-for-brain-scan-software-904807.html Ixico beats forecasts on strong demand for brain scan software https://www.biotech-capital.com/companies/news/904807/ixico-beats-forecasts-on-strong-demand-for-brain-scan-software-904807.html Tue, 15 Oct 2019 08:04:00 +0100 https://www.biotech-capital.com/companies/news/904801/open-orphan-inks-software-deal-904801.html Open Orphan inks software deal https://www.biotech-capital.com/companies/news/904801/open-orphan-inks-software-deal-904801.html Tue, 15 Oct 2019 07:56:00 +0100 https://www.biotech-capital.com/companies/news/904795/verona-pharma-to-use-industry-conference-to-expand-on-lung-disease-treatment-data-904795.html Verona Pharma to use industry conference to expand on lung disease treatment data https://www.biotech-capital.com/companies/news/904795/verona-pharma-to-use-industry-conference-to-expand-on-lung-disease-treatment-data-904795.html Tue, 15 Oct 2019 07:39:00 +0100 https://www.biotech-capital.com/companies/news/904753/bellway-and-hays-may-struggle-to-cut-through-market-gloom-904753.html Bellway and Hays may struggle to cut through market gloom https://www.biotech-capital.com/companies/news/904753/bellway-and-hays-may-struggle-to-cut-through-market-gloom-904753.html Tue, 15 Oct 2019 06:00:00 +0100 https://www.biotech-capital.com/companies/news/904761/dawson-james-securities-initiates-coverage-on-dyadic-international-with-a-buy-rating-904761.html Dawson James Securities initiates coverage on Dyadic International with a Buy rating https://www.biotech-capital.com/companies/news/904761/dawson-james-securities-initiates-coverage-on-dyadic-international-with-a-buy-rating-904761.html Mon, 14 Oct 2019 15:30:00 +0100 https://www.biotech-capital.com/companies/news/904756/ipo-roundup-post-s-protein-spinoff-targets-525m-ipo-this-week-904756.html IPO Roundup: Post's protein spinoff targets $525M IPO this week https://www.biotech-capital.com/companies/news/904756/ipo-roundup-post-s-protein-spinoff-targets-525m-ipo-this-week-904756.html Mon, 14 Oct 2019 14:40:00 +0100 https://www.biotech-capital.com/companies/news/904692/dyadic-views-president-trumps-executive-order-to-improve-flu-vaccines-as-a-major-opportunity-904692.html Dyadic views President Trump’s executive order to improve flu vaccines as a major opportunity https://www.biotech-capital.com/companies/news/904692/dyadic-views-president-trumps-executive-order-to-improve-flu-vaccines-as-a-major-opportunity-904692.html Mon, 14 Oct 2019 13:13:00 +0100 https://www.biotech-capital.com/companies/news/904612/zynerbas-cbd-gel-to-treat-fragile-x-syndrome-ventures-where-big-pharma-fears-to-tread-904612.html Zynerba’s CBD gel to treat Fragile X syndrome ventures where Big Pharma fears to tread https://www.biotech-capital.com/companies/news/904612/zynerbas-cbd-gel-to-treat-fragile-x-syndrome-ventures-where-big-pharma-fears-to-tread-904612.html Mon, 14 Oct 2019 12:30:00 +0100 https://www.biotech-capital.com/companies/news/904720/reneuron-cell-based-treatment-hailed-by-leading-non-profit-group-funding-research-into-treatments-for-retinal-degenerative-diseases-904720.html ReNeuron cell-based treatment hailed by leading non-profit group funding research into treatments for retinal degenerative diseases https://www.biotech-capital.com/companies/news/904720/reneuron-cell-based-treatment-hailed-by-leading-non-profit-group-funding-research-into-treatments-for-retinal-degenerative-diseases-904720.html Mon, 14 Oct 2019 07:56:00 +0100 https://www.biotech-capital.com/companies/news/904705/admedus-makes--transformational--sale-of-cardiocel-and-vascucel-for-362-million-904705.html Admedus makes "transformational" sale of CardioCel® and VascuCel® for $36.2 million https://www.biotech-capital.com/companies/news/904705/admedus-makes--transformational--sale-of-cardiocel-and-vascucel-for-362-million-904705.html Mon, 14 Oct 2019 06:43:00 +0100 https://www.biotech-capital.com/companies/news/904700/cellmid-secures-new-tv-shopping-agreement-for-volis-anti-ageing-hair-products-904700.html Cellmid secures new TV shopping agreement for évolis® anti-ageing hair products https://www.biotech-capital.com/companies/news/904700/cellmid-secures-new-tv-shopping-agreement-for-volis-anti-ageing-hair-products-904700.html Mon, 14 Oct 2019 02:58:00 +0100 https://www.biotech-capital.com/companies/news/904675/small-cap-movers-dart-group-ups-forecasts-as-it-mops-up-thomas-cook-customers-904675.html Small cap movers: Dart Group ups forecasts as it mops up Thomas Cook customers https://www.biotech-capital.com/companies/news/904675/small-cap-movers-dart-group-ups-forecasts-as-it-mops-up-thomas-cook-customers-904675.html Sat, 12 Oct 2019 10:00:00 +0100 https://www.biotech-capital.com/companies/news/904684/buds--duds-cannabis-stocks-conclude-a-no-good-very-bad-week-the-flowr-corporation-and-the-green-organic-dutchman-blossom-904684.html Buds & Duds: Cannabis stocks conclude a no good, very bad week; The Flowr Corporation and The Green Organic Dutchman blossom https://www.biotech-capital.com/companies/news/904684/buds--duds-cannabis-stocks-conclude-a-no-good-very-bad-week-the-flowr-corporation-and-the-green-organic-dutchman-blossom-904684.html Fri, 11 Oct 2019 16:51:00 +0100 https://www.biotech-capital.com/companies/news/904680/summit-eyes-bright-future-for-ridinilazole-904680.html Summit eyes bright future for Ridinilazole https://www.biotech-capital.com/companies/news/904680/summit-eyes-bright-future-for-ridinilazole-904680.html Fri, 11 Oct 2019 16:18:00 +0100 https://www.biotech-capital.com/companies/news/904681/proactive-snapshot-salt-lake-potash-columbus-energy-benchmark-holdings-904681.html Proactive snapshot: Salt Lake Potash, Columbus Energy, Benchmark Holdings https://www.biotech-capital.com/companies/news/904681/proactive-snapshot-salt-lake-potash-columbus-energy-benchmark-holdings-904681.html Fri, 11 Oct 2019 16:17:00 +0100 https://www.biotech-capital.com/companies/news/904583/nextech-ar-names-kashif-malik-as-chief-financial-officer-904583.html NexTech AR names Kashif Malik as chief financial officer https://www.biotech-capital.com/companies/news/904583/nextech-ar-names-kashif-malik-as-chief-financial-officer-904583.html Thu, 10 Oct 2019 13:50:00 +0100 https://www.biotech-capital.com/companies/news/904578/sensyne-health-a--buy--says-broker-as-bayer-extends-contract-904578.html Sensyne Health a 'buy' says broker as Bayer extends contract https://www.biotech-capital.com/companies/news/904578/sensyne-health-a--buy--says-broker-as-bayer-extends-contract-904578.html Thu, 10 Oct 2019 12:33:00 +0100 https://www.biotech-capital.com/companies/news/215068/motif-bio-plc-calls-time-on-iclaprim-215068.html Motif Bio PLC calls time on iclaprim https://www.biotech-capital.com/companies/news/215068/motif-bio-plc-calls-time-on-iclaprim-215068.html Thu, 10 Oct 2019 08:58:00 +0100 https://www.biotech-capital.com/companies/news/904556/motif-bio-gets-confirmation-of-requirements-for-new-iclaprim-trial-904556.html Motif Bio gets confirmation of requirements for new iclaprim trial https://www.biotech-capital.com/companies/news/904556/motif-bio-gets-confirmation-of-requirements-for-new-iclaprim-trial-904556.html Thu, 10 Oct 2019 08:24:00 +0100 https://www.biotech-capital.com/companies/news/904555/avacta-inks-collaboration-with-adc-therapeutics-sa-904555.html Avacta inks collaboration with ADC Therapeutics SA https://www.biotech-capital.com/companies/news/904555/avacta-inks-collaboration-with-adc-therapeutics-sa-904555.html Thu, 10 Oct 2019 08:18:00 +0100 https://www.biotech-capital.com/companies/news/219597/avacta-progresses-with-the-development-of-its-affimer-candidate-219597.html Avacta progresses with the development of its Affimer candidate https://www.biotech-capital.com/companies/news/219597/avacta-progresses-with-the-development-of-its-affimer-candidate-219597.html Thu, 10 Oct 2019 07:45:00 +0100 https://www.biotech-capital.com/companies/news/904525/cellmid-goes-into-trading-halt-ahead-of-proposed-capital-raising-904525.html Cellmid goes into trading halt ahead of proposed capital raising https://www.biotech-capital.com/companies/news/904525/cellmid-goes-into-trading-halt-ahead-of-proposed-capital-raising-904525.html Thu, 10 Oct 2019 00:25:00 +0100 https://www.biotech-capital.com/companies/news/904508/european-legal-cannabis-a--prime-investment-target--for-north-american-money-904508.html European legal cannabis a "prime investment target" for North American money https://www.biotech-capital.com/companies/news/904508/european-legal-cannabis-a--prime-investment-target--for-north-american-money-904508.html Wed, 09 Oct 2019 16:11:00 +0100 https://www.biotech-capital.com/companies/news/215244/faron-pharmaceuticals-makes-good-progress-with-clevegen-immunotherapy-trial-215244.html Faron Pharmaceuticals makes good progress with Clevegen immunotherapy trial https://www.biotech-capital.com/companies/news/215244/faron-pharmaceuticals-makes-good-progress-with-clevegen-immunotherapy-trial-215244.html Wed, 09 Oct 2019 15:57:00 +0100 https://www.biotech-capital.com/companies/news/904465/scapa-group-sticks-it-out-despite-contract-loss-904465.html Scapa Group sticks it out despite contract loss https://www.biotech-capital.com/companies/news/904465/scapa-group-sticks-it-out-despite-contract-loss-904465.html Wed, 09 Oct 2019 15:15:00 +0100 https://www.biotech-capital.com/companies/news/904473/gsk-recalls-heartburn-drug-over-carcinogen-risk-904473.html GSK recalls heartburn drug over carcinogen risk https://www.biotech-capital.com/companies/news/904473/gsk-recalls-heartburn-drug-over-carcinogen-risk-904473.html Wed, 09 Oct 2019 13:27:00 +0100 https://www.biotech-capital.com/companies/news/904407/aim-immunotech-says-raised-around-10m-from-public-markets-over-past-few-months-to-support-lead-drug-cancer-candidate-904407.html AIM ImmunoTech says raised around $10M from public markets over past few months to support lead drug cancer candidate https://www.biotech-capital.com/companies/news/904407/aim-immunotech-says-raised-around-10m-from-public-markets-over-past-few-months-to-support-lead-drug-cancer-candidate-904407.html Tue, 08 Oct 2019 16:40:00 +0100 https://www.biotech-capital.com/companies/news/904405/eden-pharma-hits-new-high-with-fourth-round-of-funding-904405.html Eden Pharma hits new high with fourth round of funding https://www.biotech-capital.com/companies/news/904405/eden-pharma-hits-new-high-with-fourth-round-of-funding-904405.html Tue, 08 Oct 2019 16:06:00 +0100 https://www.biotech-capital.com/companies/news/904376/bevcanna-enterprises-outlines-goals-for-next-six-months-including-moving-towards-a-product-launch-in-california-904376.html BevCanna Enterprises outlines goals for next six months, including moving towards a product launch in California https://www.biotech-capital.com/companies/news/904376/bevcanna-enterprises-outlines-goals-for-next-six-months-including-moving-towards-a-product-launch-in-california-904376.html Tue, 08 Oct 2019 15:20:00 +0100 https://www.biotech-capital.com/companies/news/904394/humanigen-inc-finds-support-for-its-strategy-in-treating-graft-versus-host-disease-in-medical-journal-article-904394.html Humanigen Inc finds support for its strategy in treating graft-versus-host disease in medical journal article https://www.biotech-capital.com/companies/news/904394/humanigen-inc-finds-support-for-its-strategy-in-treating-graft-versus-host-disease-in-medical-journal-article-904394.html Tue, 08 Oct 2019 15:15:00 +0100 https://www.biotech-capital.com/companies/news/220700/integumen-s-digital-revolution-220700.html Integumen's digital revolution https://www.biotech-capital.com/companies/news/220700/integumen-s-digital-revolution-220700.html Tue, 08 Oct 2019 10:16:00 +0100 https://www.biotech-capital.com/companies/news/219881/reneuron-looks-to-follow-up-retinitis-pigmentosa-studies-219881.html ReNeuron looks to follow up retinitis pigmentosa studies https://www.biotech-capital.com/companies/news/219881/reneuron-looks-to-follow-up-retinitis-pigmentosa-studies-219881.html Tue, 08 Oct 2019 09:54:00 +0100 https://www.biotech-capital.com/companies/news/220328/midatech-pharma-looks-ahead-to-big-18-months-as-clinical-trials-build-momentum-220328.html Midatech Pharma looks ahead to big 18 months as clinical trials build momentum https://www.biotech-capital.com/companies/news/220328/midatech-pharma-looks-ahead-to-big-18-months-as-clinical-trials-build-momentum-220328.html Tue, 08 Oct 2019 09:10:00 +0100 https://www.biotech-capital.com/companies/news/904348/midatech-pharma-starts-phase-1-trial-of-hormonal-cancer-treatment-904348.html Midatech Pharma starts phase 1 trial of hormonal cancer treatment https://www.biotech-capital.com/companies/news/904348/midatech-pharma-starts-phase-1-trial-of-hormonal-cancer-treatment-904348.html Tue, 08 Oct 2019 08:01:00 +0100 https://www.biotech-capital.com/companies/news/904259/e-therapeutics-making-good-progress-says-chief-executive-904259.html E-Therapeutics making good progress says chief executive https://www.biotech-capital.com/companies/news/904259/e-therapeutics-making-good-progress-says-chief-executive-904259.html Mon, 07 Oct 2019 16:02:00 +0100 https://www.biotech-capital.com/companies/news/903982/reneuron-hails--clear-signal--from-retinitis-pigmentosa-trials-903982.html ReNeuron hails "clear signal" from retinitis pigmentosa trials https://www.biotech-capital.com/companies/news/903982/reneuron-hails--clear-signal--from-retinitis-pigmentosa-trials-903982.html Mon, 07 Oct 2019 16:00:00 +0100 https://www.biotech-capital.com/companies/news/904299/genprex-believes-in-non-viral-delivery-as-the-next-evolution-in-gene-therapy-and-scientific-paper-agrees-904299.html Genprex believes in non-viral delivery as the next evolution in gene therapy, and scientific paper agrees https://www.biotech-capital.com/companies/news/904299/genprex-believes-in-non-viral-delivery-as-the-next-evolution-in-gene-therapy-and-scientific-paper-agrees-904299.html Mon, 07 Oct 2019 15:40:00 +0100 https://www.biotech-capital.com/companies/news/904296/summit-therapeutics-antibiotic-leaves-gut-healthy-but-kills-cdifficile-904296.html Summit Therapeutics antibiotic leaves gut healthy but kills C.difficile https://www.biotech-capital.com/companies/news/904296/summit-therapeutics-antibiotic-leaves-gut-healthy-but-kills-cdifficile-904296.html Mon, 07 Oct 2019 15:24:00 +0100 https://www.biotech-capital.com/companies/news/904287/sensyne-health-readies-for-us-launch-as-it-closes-pivotal-year-904287.html Sensyne Health readies for US launch as it closes “pivotal year” https://www.biotech-capital.com/companies/news/904287/sensyne-health-readies-for-us-launch-as-it-closes-pivotal-year-904287.html Mon, 07 Oct 2019 14:24:00 +0100 https://www.biotech-capital.com/companies/news/218067/alliance-pharma-hints-at-further-acquisitions-as-it-reports-sales-up-by-one-third-in-half-year-results-218067.html Alliance Pharma hints at further acquisitions as it reports sales up by one third in half-year results https://www.biotech-capital.com/companies/news/218067/alliance-pharma-hints-at-further-acquisitions-as-it-reports-sales-up-by-one-third-in-half-year-results-218067.html Mon, 07 Oct 2019 10:01:00 +0100 https://www.biotech-capital.com/companies/news/220864/genedrive-gets-boost-as-nhs-approves-antibiotic-diagnostic-trial-220864.html Genedrive gets boost as NHS approves antibiotic diagnostic trial https://www.biotech-capital.com/companies/news/220864/genedrive-gets-boost-as-nhs-approves-antibiotic-diagnostic-trial-220864.html Mon, 07 Oct 2019 09:54:00 +0100 https://www.biotech-capital.com/companies/news/218516/e-therapeutics-hopeful-of-securing-more-collaboration-deals-in-2019-218516.html e-Therapeutics hopeful of securing more collaboration deals in 2019 https://www.biotech-capital.com/companies/news/218516/e-therapeutics-hopeful-of-securing-more-collaboration-deals-in-2019-218516.html Mon, 07 Oct 2019 09:40:00 +0100 https://www.biotech-capital.com/companies/news/214111/maxcyte-fighting-cancer-battle-on-two-fronts-via-experimental-targeted-treatment-and-technology-licensing-deals-214111.html Maxcyte fighting cancer battle on two fronts via experimental targeted treatment and technology licensing deals https://www.biotech-capital.com/companies/news/214111/maxcyte-fighting-cancer-battle-on-two-fronts-via-experimental-targeted-treatment-and-technology-licensing-deals-214111.html Mon, 07 Oct 2019 09:32:00 +0100 https://www.biotech-capital.com/companies/news/904253/maxcyte-licenses-cell-engineering-technology-to-nasdaq-listed-editas-904253.html Maxcyte licenses cell engineering technology to Nasdaq-listed Editas https://www.biotech-capital.com/companies/news/904253/maxcyte-licenses-cell-engineering-technology-to-nasdaq-listed-editas-904253.html Mon, 07 Oct 2019 08:49:00 +0100 https://www.biotech-capital.com/companies/news/904246/genedrive-gets-approval-to-trial-baby-deafness-test-in-nhs-hospitals-904246.html Genedrive gets approval to trial baby deafness test in NHS hospitals https://www.biotech-capital.com/companies/news/904246/genedrive-gets-approval-to-trial-baby-deafness-test-in-nhs-hospitals-904246.html Mon, 07 Oct 2019 08:03:00 +0100 https://www.biotech-capital.com/companies/news/904206/small-cap-movers-infrastrata-buoyant-after-rescuing-titanic-shipyard-904206.html Small cap movers: InfraStrata buoyant after rescuing Titanic shipyard https://www.biotech-capital.com/companies/news/904206/small-cap-movers-infrastrata-buoyant-after-rescuing-titanic-shipyard-904206.html Sat, 05 Oct 2019 10:00:00 +0100 https://www.biotech-capital.com/companies/news/904209/buds--duds-cannabis-stocks-remain-mostly-flat-heading-into-the-weekend-canopy-growth-falls-after-constellation-brands-writedown-904209.html Buds & Duds: Cannabis stocks remain mostly flat heading into the weekend; Canopy Growth falls after Constellation Brands writedown https://www.biotech-capital.com/companies/news/904209/buds--duds-cannabis-stocks-remain-mostly-flat-heading-into-the-weekend-canopy-growth-falls-after-constellation-brands-writedown-904209.html Fri, 04 Oct 2019 16:15:00 +0100 https://www.biotech-capital.com/companies/news/904211/proactive-snapshot-zoetic-international-columbus-energy-angle-904211.html Proactive snapshot: Zoetic International, Columbus Energy, ANGLE https://www.biotech-capital.com/companies/news/904211/proactive-snapshot-zoetic-international-columbus-energy-angle-904211.html Fri, 04 Oct 2019 16:13:00 +0100 https://www.biotech-capital.com/companies/news/904184/litelink-technologies-unveils-new-strategic-tie-up-with-segra-international-for-cannabis-tracking-904184.html LiteLink Technologies unveils new strategic tie-up with Segra International for cannabis tracking https://www.biotech-capital.com/companies/news/904184/litelink-technologies-unveils-new-strategic-tie-up-with-segra-international-for-cannabis-tracking-904184.html Fri, 04 Oct 2019 15:39:00 +0100 https://www.biotech-capital.com/companies/news/904179/arecor-progresses-with-insulin-candidate-clinical-trial-904179.html Arecor progresses with insulin candidate clinical trial https://www.biotech-capital.com/companies/news/904179/arecor-progresses-with-insulin-candidate-clinical-trial-904179.html Fri, 04 Oct 2019 11:26:00 +0100 https://www.biotech-capital.com/companies/news/904176/astrazeneca-gets-us-clearance-for-asthma-pen-904176.html AstraZeneca gets US clearance for asthma pen https://www.biotech-capital.com/companies/news/904176/astrazeneca-gets-us-clearance-for-asthma-pen-904176.html Fri, 04 Oct 2019 10:23:00 +0100 https://www.biotech-capital.com/companies/news/904157/angle-says-queen-mary-university-patent-could-pave-the-way-for-a-new-use-for-its-technology-904157.html ANGLE says Queen Mary University patent could pave the way for a new use for its technology https://www.biotech-capital.com/companies/news/904157/angle-says-queen-mary-university-patent-could-pave-the-way-for-a-new-use-for-its-technology-904157.html Fri, 04 Oct 2019 07:29:00 +0100 https://www.biotech-capital.com/companies/news/904112/bevcanna-enterprises-poised-and-primed-for-infused-drinks-legalization-in-canada-with-higharchy-ventures-deal-904112.html BevCanna Enterprises poised and primed for infused drinks legalization in Canada with Higharchy Ventures deal https://www.biotech-capital.com/companies/news/904112/bevcanna-enterprises-poised-and-primed-for-infused-drinks-legalization-in-canada-with-higharchy-ventures-deal-904112.html Thu, 03 Oct 2019 18:35:00 +0100 https://www.biotech-capital.com/companies/news/904119/exactus-inc-launches-new-e-commerce-site-initiates-knowyourhemp-buy-back-campaign-904119.html Exactus Inc launches new e-commerce site, initiates #knowyourhemp buy back campaign https://www.biotech-capital.com/companies/news/904119/exactus-inc-launches-new-e-commerce-site-initiates-knowyourhemp-buy-back-campaign-904119.html Thu, 03 Oct 2019 15:05:00 +0100 https://www.biotech-capital.com/companies/news/904110/immunoprecise-antibodies-appoints-industry-veteran-brian-lundstrom-to-its-board-904110.html ImmunoPrecise Antibodies appoints industry veteran Brian Lundstrom to its board https://www.biotech-capital.com/companies/news/904110/immunoprecise-antibodies-appoints-industry-veteran-brian-lundstrom-to-its-board-904110.html Thu, 03 Oct 2019 14:40:00 +0100 https://www.biotech-capital.com/companies/news/904114/shares-in-netscientific-up-strongly-after-portfolio-company-s-drug-is-given-merck-boost-904114.html Shares in NetScientific up strongly after portfolio company's drug is given Merck boost https://www.biotech-capital.com/companies/news/904114/shares-in-netscientific-up-strongly-after-portfolio-company-s-drug-is-given-merck-boost-904114.html Thu, 03 Oct 2019 14:38:00 +0100 https://www.biotech-capital.com/companies/news/904115/when-did-you-get-so-big-billion-pound-companies-that-maybe-you-thought-weren-t-904115.html When did you get so big? Billion-pound companies that maybe you thought weren't https://www.biotech-capital.com/companies/news/904115/when-did-you-get-so-big-billion-pound-companies-that-maybe-you-thought-weren-t-904115.html Thu, 03 Oct 2019 14:14:00 +0100 https://www.biotech-capital.com/companies/news/904109/tissue-regenix-making-headway-904109.html Tissue Regenix making headway https://www.biotech-capital.com/companies/news/904109/tissue-regenix-making-headway-904109.html Thu, 03 Oct 2019 14:10:00 +0100 https://www.biotech-capital.com/companies/news/904100/summit-therapeutics-shares-rise-on-phase-ii-cdifficile-data-904100.html Summit Therapeutics shares rise on phase II c.difficile data https://www.biotech-capital.com/companies/news/904100/summit-therapeutics-shares-rise-on-phase-ii-cdifficile-data-904100.html Thu, 03 Oct 2019 12:52:00 +0100 https://www.biotech-capital.com/companies/news/904073/genedrive-expects-to-make-good-progress-with-diagnostics-pipeline-904073.html Genedrive expects to make good progress with diagnostics pipeline https://www.biotech-capital.com/companies/news/904073/genedrive-expects-to-make-good-progress-with-diagnostics-pipeline-904073.html Thu, 03 Oct 2019 07:56:00 +0100 https://www.biotech-capital.com/companies/news/904070/tissue-regenix-develops-product-extension-to-be-used-in-female-pelvic-medicine-904070.html Tissue Regenix develops product extension to be used in female pelvic medicine https://www.biotech-capital.com/companies/news/904070/tissue-regenix-develops-product-extension-to-be-used-in-female-pelvic-medicine-904070.html Thu, 03 Oct 2019 07:30:00 +0100 https://www.biotech-capital.com/companies/news/900667/amphion-innovations-keen-to-hold-onto-polarean-imaging-stake-900667.html Amphion Innovations keen to hold onto Polarean Imaging stake https://www.biotech-capital.com/companies/news/900667/amphion-innovations-keen-to-hold-onto-polarean-imaging-stake-900667.html Thu, 03 Oct 2019 07:29:00 +0100 https://www.biotech-capital.com/companies/news/904031/buds--duds-bloodletting-continues-for-cannabis-stocks-but-ventura-cannabis-and-wellness-shines-on-new-financials-904031.html Buds & Duds: Bloodletting continues for cannabis stocks but Ventura Cannabis and Wellness shines on new financials https://www.biotech-capital.com/companies/news/904031/buds--duds-bloodletting-continues-for-cannabis-stocks-but-ventura-cannabis-and-wellness-shines-on-new-financials-904031.html Wed, 02 Oct 2019 16:58:00 +0100 https://www.biotech-capital.com/companies/news/904002/cytodyn-wins-fda-clearance-to-begin-phase-2-trial-of-its-drug-leronlimab-in-patients-with-nash-904002.html CytoDyn wins FDA clearance to begin Phase 2 trial of its drug leronlimab in patients with NASH https://www.biotech-capital.com/companies/news/904002/cytodyn-wins-fda-clearance-to-begin-phase-2-trial-of-its-drug-leronlimab-in-patients-with-nash-904002.html Wed, 02 Oct 2019 15:50:00 +0100 https://www.biotech-capital.com/companies/news/904015/walgreens-and-rite-aid-join-cvs-health-in-discontinuing-sales-of-popular-heartburn-drug-zantac-904015.html Walgreens and Rite Aid join CVS Health in discontinuing sales of popular heartburn drug Zantac https://www.biotech-capital.com/companies/news/904015/walgreens-and-rite-aid-join-cvs-health-in-discontinuing-sales-of-popular-heartburn-drug-zantac-904015.html Wed, 02 Oct 2019 14:30:00 +0100 https://www.biotech-capital.com/companies/news/903996/cello-health-sells-social-media-analytics-software-business-for-45mln-903996.html Cello Health sells social media analytics software business for £4.5mln https://www.biotech-capital.com/companies/news/903996/cello-health-sells-social-media-analytics-software-business-for-45mln-903996.html Wed, 02 Oct 2019 12:21:00 +0100